Drugs / favezelimab/pembrolizumab
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05508867 | Oct 2022 → Sep 2025 | classic Hodgkin lymphoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | favezelimab/pembrolizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05508867 ↗ |
| Known as | MK-4280A | “Researchers want to learn if people who receive coformulated favezelimab/pembrolizumab (MK-4280A) live longer without the cancer getting worse compared to those who receive...” NCT05508867 ↗ |
| Route | Intravenous | “by intravenous (IV) infusion” NCT05508867 ↗ |